Table 1. Baseline Characteristics of Study Population.
| Characteristic | All Patients (N=41) |
|---|---|
| Age (years, Mean ± SE) | 63 ± 1.5 |
| Male sex N(%) | 26 (63) |
| Caucasian race N(%) | 34 (83) |
| Hypertension N(%) | 32 (78) |
| Diabetes Mellitus N(%) | 9 (22) |
| Current and previous tobacco smoking (%) | 22 (54) |
| History of Myocardial Infarction N(%) | 22 (54) |
| History of Percutaneous Coronary Intervention N(%) | 38 (93%) |
| History of Coronary Artery Bypass Graft Surgery N(%) | 2 (5%) |
| Medications | |
| Aspirin N(%) | 39 (95) |
| Statins N(%) | 34 (83) |
| Beta-blockers N(%) | 27 (66) |
| Angiotensin converting enzymes inhibitors N(%) | 21 (51) |
| Calcium channel blockers N(%) | 9 (22) |
| Fasting Lipid Profile (Mean ± SE) | |
| Total cholesterol (mg/dL) | 163 ± 7 |
| Triglycerides (mg/dL) | 128 ± 11 |
| High density lipoprotein (mg/dL) | 53 ± 3 |
| Low density lipoprotein (mg/dL) | 87 ± 6 |
| Oxidative Stress Markers (Mean ± SE) | |
| Cystine (μM) | 84.11 ± 6.12 |
| Cysteine (μM) | 12.89 ± 1.13 |
| Eh Cysteine/Cystine Ratio | -75.37 ± 1.88 |
| Glutathione (μM) | 1.56 ± 0.12 |
| Oxidized glutathione (μM) | 0.28 ± 0.11 |
| Eh Glutathione/Oxidized Glutathione Ratio | -129.89 ± 3.25 |
| Inflammatory Markers (Mean ± SE) | |
| Hs-CRP (mg/L) | 2.44 ± 0.43 |
| CD40 Ligand (pg/ml) | 1558.01 ± 360.41 |
| Vascular Function (Mean ± SE) | |
| Flow Mediated Vasodilation (%) | 4.90 ± 0.59 |
| Nitroglycerin Mediated Vasodilation (%) | 18.54 ± 1.58 |
| Reactive Hyperemia Index | 2.40 ± 0.80 |
| Augmentation Index at 75 beats per minute | 25.67 ± 1.47 |
| Pulse Wave Velocity (m/s) | 8.75 ± 0.37 |
| Endothelial Progenitor Cells (Mean ± SE) | |
| CD34+ (cells/μl) | 1.22 ± 0.13 |
| CD34+/133+ (cells/μl) | 0.69 ± 0.07 |
| CD34+/VEGF2R+ (cells/μl) | 0.08 ± 0.02 |
| CD34+/CD133+/VEGF2R+ (cells/μl) | 0.07 ± 0.02 |